Free Trial

Genus (GNS) Competitors

GBX 1,848
+80.00 (+4.52%)
(As of 07/12/2024 ET)

GNS vs. BTG, ABC, ONT, ERGO, PRTC, SLN, OXB, HZD, AVCT, and BVXP

Should you be buying Genus stock or one of its competitors? The main competitors of Genus include BTG (BTG), Abcam (ABC), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), PureTech Health (PRTC), Silence Therapeutics (SLN), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry.

Genus vs.

Genus (LON:GNS) and BTG (LON:BTG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.

Genus has a net margin of 4.96% compared to BTG's net margin of 0.00%. Genus' return on equity of 5.27% beat BTG's return on equity.

Company Net Margins Return on Equity Return on Assets
Genus4.96% 5.27% 3.18%
BTG N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genus
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
BTG
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

BTG received 269 more outperform votes than Genus when rated by MarketBeat users. Likewise, 73.95% of users gave BTG an outperform vote while only 70.56% of users gave Genus an outperform vote.

CompanyUnderperformOutperform
GenusOutperform Votes
350
70.56%
Underperform Votes
146
29.44%
BTGOutperform Votes
619
73.95%
Underperform Votes
218
26.05%

78.5% of Genus shares are held by institutional investors. 0.7% of Genus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genus has higher earnings, but lower revenue than BTG. BTG is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genus£673.10M1.81£33.40M£0.493,771.43
BTG£914.10M3.57N/A£28.5029.47

In the previous week, Genus' average media sentiment score of 0.00 equaled BTG'saverage media sentiment score.

Company Overall Sentiment
Genus Neutral
BTG Neutral

Summary

Genus beats BTG on 6 of the 11 factors compared between the two stocks.

Get Genus News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNS vs. The Competition

MetricGenusBiotechnology IndustryMedical SectorLON Exchange
Market Cap£1.22B£169.10M£5.31B£1.58B
Dividend Yield1.73%3.43%2.83%11.27%
P/E Ratio3,771.43251.6499.451,851.18
Price / Sales1.8117,293.662,167.30358,635.28
Price / Cash50.5611.7935.2435.16
Price / Book2.116.574.902.71
Net Income£33.40M-£18.88M£110.78M£160.65M
7 Day Performance5.72%3.69%6.14%75.20%
1 Month Performance4.41%1.83%4.31%73.17%
1 Year Performance-22.03%15.20%5.54%94.06%

Genus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTG
BTG
0 of 5 stars
0.00 / 5 stars
N/AN/A+0.0%£3.26B£914.10M29.471,631
ABC
Abcam
0 of 5 stars
0.00 / 5 stars
N/AN/A+0.0%£2.81B£350.40M20,433.331,650Gap Up
High Trading Volume
ONT
Oxford Nanopore Technologies
2.226 of 5 stars
2.23 / 5 stars
GBX 104.50
-0.1%
GBX 276.75
+164.8%
-54.3%£901.41M£169.67M-550.001,238News Coverage
ERGO
Ergomed
0 of 5 stars
0.00 / 5 stars
N/AGBX 1,400
+∞
+36.6%£701.00M£152.09M4,641.381,400
PRTC
PureTech Health
0 of 5 stars
0.00 / 5 stars
GBX 186.80
+1.2%
N/A-19.0%£505.13M£3.33M-983.16300Positive News
SLN
Silence Therapeutics
0 of 5 stars
0.00 / 5 stars
N/AN/A+0.0%£480.35M£11.35M-11.0174High Trading Volume
OXB
Oxford Biomedica
0.2835 of 5 stars
0.28 / 5 stars
GBX 330
-0.8%
GBX 410
+24.2%
-18.6%£330M£89.54M-202.45891
HZD
Horizon Discovery Group plc (HZD.L)
0 of 5 stars
0.00 / 5 stars
N/AN/AN/A£302.98M£54.63M-33.55416
AVCT
Avacta Group
0 of 5 stars
0.00 / 5 stars
GBX 67.80
+1.2%
N/A-22.7%£243.43M£23.25M-753.33120High Trading Volume
BVXP
Bioventix
0 of 5 stars
0.00 / 5 stars
GBX 4,425
flat
N/A+6.8%£230.99M£13.60M2,714.7212News Coverage

Related Companies and Tools

This page (LON:GNS) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners